Peter M. Richieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter M. Richieri has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Bidish Patel
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
11 shared publications - David T. Ting
Krantz Family Center for Cancer Research, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, Massachusetts
11 shared publications - Alexandra S. Rojas
Mass General Cancer Center Harvard Medical School 02129 Charlestown MA USA
10 shared publications - Benjamin D. Greenbaum
Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
10 shared publications - Eunae You
Mass General Cancer Center Harvard Medical School 02129 Charlestown MA USA
10 shared publications - Ildiko E. Phillips
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
10 shared publications
Latest Publications
- 8 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF15
Comparative Transcriptomic and Immune Profiling Reveals a Shared Molecular Identity between Clear Cell Odontogenic Carcinoma and Hyalinizing Clear Cell Carcinoma
Clear cell odontogenic carcinoma (CCOC) and hyalinizing clear cell carcinoma (HCCC), rare head and neck malignancies with recurrent EWSR1::CREB family fusions, show overlapping morphologic and immunophenotypic features; no standardized systemic therapy for either exists. Given tissue constraints, the molecular relationship of CCOC and HCCC to each other and to relevant head and neck cancers remains incompletely defined. We used spatial transcriptomic profiling, multiplex immunofluorescence (mIF), and RNA in situ hybridization (RNA-ISH) to characterize the molecular and immune landscape of CCOC, HCCC, and relevant head and neck and fusion-associated comparators. Key transcriptomic findings were validated by RNA-ISH (image-based signal quantification), complemented by mIF-defined immune cell composition, antigen presentation features, and architecture. CCOC and HCCC demonstrated highly overlapping transcriptomic profiles; clear cell sarcoma (CCS), despite shared EWSR1::CREB family fusion contexts, remained distinct. CCOC and HCCC showed enrichment of a shared epithelial secretory program, with ductal, luminal, and regulated secretory pathway features. Insulin-like growth factor (IGF) 2, among the most enriched shared transcripts, showed strong tumor cell–associated expression. Candidate targets included TACSTD2 (TROP2), FGFR2, FOLR1, KDR, MSLN, and MUC1. mIF profiling demonstrated low B2M and human leukocyte antigen (HLA) I expression, sparse lymphoid infiltration, minimal PD-L1 expression, and an overall immune-cold phenotype, consistent with impaired antigen presentation. Transcriptome-wide evidence showed that CCOC and HCCC share a common molecular identity, particularly distinct from myoepithelial carcinoma and squamous cell carcinoma. Implications: This study—the most comprehensive molecular comparison to date of CCOC and HCCC, set against each other and relevant differential diagnoses—establishes a shared molecular framework that may improve diagnostic classification and guide biomarker and therapeutic development for these exceptionally rare tumors.
- 8 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF15
Comparative Transcriptomic and Immune Profiling Reveals a Shared Molecular Identity between Clear Cell Odontogenic Carcinoma and Hyalinizing Clear Cell Carcinoma
Clear cell odontogenic carcinoma (CCOC) and hyalinizing clear cell carcinoma (HCCC), rare head and neck malignancies with recurrent EWSR1::CREB family fusions, show overlapping morphologic and immunophenotypic features; no standardized systemic therapy for either exists. Given tissue constraints, the molecular relationship of CCOC and HCCC to each other and to relevant head and neck cancers remains incompletely defined. We used spatial transcriptomic profiling, multiplex immunofluorescence (mIF), and RNA in situ hybridization (RNA-ISH) to characterize the molecular and immune landscape of CCOC, HCCC, and relevant head and neck and fusion-associated comparators. Key transcriptomic findings were validated by RNA-ISH (image-based signal quantification), complemented by mIF-defined immune cell composition, antigen presentation features, and architecture. CCOC and HCCC demonstrated highly overlapping transcriptomic profiles; clear cell sarcoma (CCS), despite shared EWSR1::CREB family fusion contexts, remained distinct. CCOC and HCCC showed enrichment of a shared epithelial secretory program, with ductal, luminal, and regulated secretory pathway features. Insulin-like growth factor (IGF) 2, among the most enriched shared transcripts, showed strong tumor cell–associated expression. Candidate targets included TACSTD2 (TROP2), FGFR2, FOLR1, KDR, MSLN, and MUC1. mIF profiling demonstrated low B2M and human leukocyte antigen (HLA) I expression, sparse lymphoid infiltration, minimal PD-L1 expression, and an overall immune-cold phenotype, consistent with impaired antigen presentation. Transcriptome-wide evidence showed that CCOC and HCCC share a common molecular identity, particularly distinct from myoepithelial carcinoma and squamous cell carcinoma. Implications: This study—the most comprehensive molecular comparison to date of CCOC and HCCC, set against each other and relevant differential diagnoses—establishes a shared molecular framework that may improve diagnostic classification and guide biomarker and therapeutic development for these exceptionally rare tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S3. Key resources table
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S3. Key resources table
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S1. LINE-1 ORF1p function in PDAC and other cell lines. Supplementary Figure S2. Titration of Dox concentration to rescue ORF1p expression and evaluation of micronuclei-mediated STING activation. Supplementary Figure S3. ORF1p knockdown sensitizes repeat RNA-induced IFN response. Supplementary Figure S4. ORF1p cellular localization and evaluation of RNA editing protein function. Supplementary Figure S5. EM-related gene expression and response to drugs upon ORF1 knockdown. Supplementary Figure S6. ORF1 knockdown in vivo suppresses tumor progression by altering the TME. Supplementary Figure S7. Analysis of single-cell spatial neighborhoods.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S1. LINE-1 ORF1p function in PDAC and other cell lines. Supplementary Figure S2. Titration of Dox concentration to rescue ORF1p expression and evaluation of micronuclei-mediated STING activation. Supplementary Figure S3. ORF1p knockdown sensitizes repeat RNA-induced IFN response. Supplementary Figure S4. ORF1p cellular localization and evaluation of RNA editing protein function. Supplementary Figure S5. EM-related gene expression and response to drugs upon ORF1 knockdown. Supplementary Figure S6. ORF1 knockdown in vivo suppresses tumor progression by altering the TME. Supplementary Figure S7. Analysis of single-cell spatial neighborhoods.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S2. Classification of FOVs based on LINE-1 ORF1p expression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S2. Classification of FOVs based on LINE-1 ORF1p expression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S1. List of proteins localized in PBs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S1. List of proteins localized in PBs.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Data from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that requires mechanisms to manage this repeat “viral” load and attenuate innate immune responses. In this study, we show that the long interspersed nuclear element 1 (LINE-1) open reading frame 1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor–mediated antiviral response that is independent of retrotransposition. Suppression of ORF1p using short hairpin RNA induces innate immune responses through the double-stranded RNA (dsRNA) sensors RIG-I and MAVS. Low ORF1p PDAC cell lines have suppressed expression of pathogen recognition receptors demonstrating convergent mechanisms to suppress innate immune signaling. Localization of ORF1p in processing bodies with the dsRNA helicase MOV10 was found to be important for these antiviral responses. Loss of ORF1p resulted in significant growth reduction in tumorspheres and mouse xenografts with an enriched epithelial cell state, and high ORF1p expression was associated with worsened survival in a cohort of human patients with PDAC.Significance:This study uncovers PDAC-specific mechanisms that dampen immune responses to viral-repeat RNA via long interspersed nuclear element 1 ORF1p. Suppression of ORF1p activates antiviral responses, reducing tumor growth and epithelial–mesenchymal transition. High ORF1p expression correlates with poor prognosis, highlighting its potential as a therapeutic target for PDAC.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that requires mechanisms to manage this repeat “viral” load and attenuate innate immune responses. In this study, we show that the long interspersed nuclear element 1 (LINE-1) open reading frame 1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor–mediated antiviral response that is independent of retrotransposition. Suppression of ORF1p using short hairpin RNA induces innate immune responses through the double-stranded RNA (dsRNA) sensors RIG-I and MAVS. Low ORF1p PDAC cell lines have suppressed expression of pathogen recognition receptors demonstrating convergent mechanisms to suppress innate immune signaling. Localization of ORF1p in processing bodies with the dsRNA helicase MOV10 was found to be important for these antiviral responses. Loss of ORF1p resulted in significant growth reduction in tumorspheres and mouse xenografts with an enriched epithelial cell state, and high ORF1p expression was associated with worsened survival in a cohort of human patients with PDAC.Significance:This study uncovers PDAC-specific mechanisms that dampen immune responses to viral-repeat RNA via long interspersed nuclear element 1 ORF1p. Suppression of ORF1p activates antiviral responses, reducing tumor growth and epithelial–mesenchymal transition. High ORF1p expression correlates with poor prognosis, highlighting its potential as a therapeutic target for PDAC.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S2. Classification of FOVs based on LINE-1 ORF1p expression.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S2. Classification of FOVs based on LINE-1 ORF1p expression.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S3. Key resources table
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S3. Key resources table
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S1. List of proteins localized in PBs.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Table S1. List of proteins localized in PBs.
- Open Access
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S1. LINE-1 ORF1p function in PDAC and other cell lines. Supplementary Figure S2. Titration of Dox concentration to rescue ORF1p expression and evaluation of micronuclei-mediated STING activation. Supplementary Figure S3. ORF1p knockdown sensitizes repeat RNA-induced IFN response. Supplementary Figure S4. ORF1p cellular localization and evaluation of RNA editing protein function. Supplementary Figure S5. EM-related gene expression and response to drugs upon ORF1 knockdown. Supplementary Figure S6. ORF1 knockdown in vivo suppresses tumor progression by altering the TME. Supplementary Figure S7. Analysis of single-cell spatial neighborhoods.
- 2 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
Supplementary Figure S1. LINE-1 ORF1p function in PDAC and other cell lines. Supplementary Figure S2. Titration of Dox concentration to rescue ORF1p expression and evaluation of micronuclei-mediated STING activation. Supplementary Figure S3. ORF1p knockdown sensitizes repeat RNA-induced IFN response. Supplementary Figure S4. ORF1p cellular localization and evaluation of RNA editing protein function. Supplementary Figure S5. EM-related gene expression and response to drugs upon ORF1 knockdown. Supplementary Figure S6. ORF1 knockdown in vivo suppresses tumor progression by altering the TME. Supplementary Figure S7. Analysis of single-cell spatial neighborhoods.